menu
Hydroxychloroquine Market 2021-2026: Industry Size, Share, Trends and Forecast
Hydroxychloroquine Market 2021-2026: Industry Size, Share, Trends and Forecast
The global hydroxychloroquine market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to exhibit robust growth during 2021-2026.

According to the latest report by IMARC Group, titled “Hydroxychloroquine Market Size: Global Industry Trends, Share, Size, Opportunity and Forecast 2021-2026,”The global hydroxychloroquine market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to exhibit robust growth during 2021-2026.

Hydroxychloroquine (HCQ) is a derivative of chloroquine with the chemical formula C18H26ClN3O. It is a chemotherapeutic agent drug that was primarily used to suppress and treat acute attacks of malaria. It is widely known to be effective against the erythrocytic forms of malarial parasites. Apart from this, it is extensively utilized for the treatment of numerous autoimmune conditions. For instance, it is used for alleviating skin problems in lupus as well as avoiding pain or swelling caused due to arthritis. It is also being employed as a possible treatment of the rapidly spreading coronavirus disease (COVID-19) due to the immunosuppressive, anti-autophagy and antimalarial properties offered by the drug.

As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the industry behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.

Global Hydroxychloroquine Market Trends:

The market is primarily driven by the rapid outbreak of COVID-19 across the globe. Since HCQ is widely being used as a potential treatment of the same, numerous clinical trials and experiments are currently underway to determine the efficacy of the drug against the virus. The results of these trials are expected to ascertain the positive demand for the drug on the global level. Apart from this, the increasing occurrence of malaria and various other chronic diseases across developing and underdeveloped countries are expected to provide an impetus to the market growth. The market is further driven by the growing incidences of autoimmune diseases, such as lupus erythematosus and rheumatoid arthritis, among individuals. This, along with the growing population and increasing health awareness amid masses, is anticipated to boost the uptake of HCQ. Extensive research and development (R&D) activities are also being conducted by several players in the field of medical sciences. This, coupled with the rising healthcare spending by several governments and the implementation of favorable government policies to promote global health, is expected to create a positive outlook for the market.

Request Free Sample Report: https://www.imarcgroup.com/hydroxychloroquine-market/requestsample

Global Hydroxychloroquine Market 2021-2026 Analysis and Segmentation:

Competitive Landscape:

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.

Amneal Pharmaceuticals Inc., Cardinal Health Inc., Cipla Ltd., Ipca Laboratories Ltd., Laurus Labs, Lupin Limited, Mylan N.V., Novartis AG, Prasco Laboratories, Dr. Reddy’s Laboratories Ltd., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Torrent Pharma, Zydus Cadila, etc.

The report has segmented the market on the basis on type, region, distribution, application,grade and administration

Breakup by Dosage Type:

  • 200 Mg
  • 300 Mg
  • 400 Mg
  • Others

Breakup by Distribution:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Breakup by Application:

  • Rheumatoid Arthritis
  • Lupus Erythematosus
  • Malaria
  • Coronavirus (COVID-19)
  • Others

Breakup by Grade:

  • USP Standards Grade
  • EP Standards Grade
  • Pharmaceutical Standards Grade
  • Others

Breakup by Route of Administration:

  • Oral
  • Intravenous

Breakup by Region:

  • North America: (United States, Canada)
  • Asia Pacific: (China, Japan,India, South Korea, Australia, Indonesia, Others)
  • Europe: (Germany, France,United Kingdom, Italy, Spain, Russia, Others)
  • Latin America: (Brazil, Mexico, Others)
  • Middle East and Africa

Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/hydroxychloroquine-market

If you want latest primary and secondary data (2021-2026) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.

Key highlights of the report:

  • Market Performance (2015-2020)
  • Market Outlook (2021- 2026)
  • Porter’s Five Forces Analysis
  • Market Drivers and Success Factors
  • SWOT Analysis
  • Value Chain
  • Comprehensive Mapping of the Competitive Landscape

If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800